Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
Matthew Austin(Amgen (United States)), Andreas Grauer(Omeros Corporation (United States)), Cesar Libanati(Amgen (United States)), David L. Kendler(University of British Columbia), José Zanchetta(Universidad del Salvador), Beatriz Oliveri(Universidad de Buenos Aires), Douglas C. Bauer(University of California, San Francisco), Michael R. McClung(Bone Health and Osteoporosis Foundation), Eric Vittinghoff(University of California, San Francisco), Steven R. Cummings(University of California, San Francisco), Michael A. Bolognese, Steven Boonen(KU Leuven), Ian R. Reid(University of Auckland), Richard Eastell(University of Sheffield), Federico Hawkins(Hospital Universitario 12 De Octubre), Gerolamo Bianchi, Ethel S. Siris(Columbia University Irving Medical Center), Cristiano A. F. Zerbini(Centro Paulista de Investigação Clinica), Silvano Adami(University of Verona), Claus Christiansen(VA Eastern Colorado Health Care System), Yuching Yang(Amgen (United States))
Cited by 181
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
The diagnosis of osteoporosis
|Journal of Bone and Mineral Research|1994|3.9k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k